QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
QQQ   332.28 (-0.23%)
AAPL   173.03 (-0.09%)
MSFT   292.71 (-0.26%)
META   179.47 (-0.79%)
GOOGL   121.70 (-0.31%)
AMZN   144.78 (+1.12%)
TSLA   919.69 (-0.89%)
NVDA   188.79 (-0.80%)
NIO   20.91 (-1.83%)
BABA   92.65 (-1.65%)
AMD   100.20 (-0.80%)
MU   63.86 (-1.30%)
T   18.57 (+0.98%)
CGC   3.78 (-1.05%)
F   16.43 (+0.67%)
GE   81.07 (+1.58%)
DIS   124.96 (+0.56%)
AMC   24.81 (+2.48%)
PYPL   102.08 (+0.56%)
PFE   49.86 (+0.22%)
NFLX   245.69 (-1.37%)
NASDAQ:HGEN

Humanigen - HGEN Stock Forecast, Price & News

$0.37
-0.01 (-2.64%)
(As of 08/16/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.37
$0.38
50-Day Range
$0.35
$3.02
52-Week Range
$0.35
$18.22
Volume
5.85 million shs
Average Volume
4.12 million shs
Market Capitalization
$26.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.50

Humanigen MarketRank™ Forecast

Analyst Rating
Hold
1.67 Rating Score
Upside/​Downside
4,913.6% Upside
$18.50 Price Target
Short Interest
Healthy
14.16% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.62mentions of Humanigen in the last 14 days
Based on 9 Articles This Week
Insider Trading
Acquiring Shares
$1.56 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.15) to ($0.72) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.26 out of 5 stars

Medical Sector

375th out of 1,124 stocks

Pharmaceutical Preparations Industry

181st out of 555 stocks

HGEN stock logo

About Humanigen (NASDAQ:HGEN) Stock

Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called 'cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is also being studied in conjunction with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1. Ifabotuzumab has been evaluated in a Phase 1 study of glioblastoma multiforme that showed tumor specific targeting of all known tumor sites with no normal tissue uptake. HGEN005 is being explored as a treatment for a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Cantor Fitzgerald downgraded Humanigen from an "overweight" rating to a "neutral" rating in a research report on Wednesday, July 13th. HC Wainwright downgraded Humanigen from a "buy" rating to a "neutral" rating in a research report on Wednesday, July 13th. Roth Capital downgraded Humanigen from a "buy" rating to a "neutral" rating in a report on Wednesday, July 13th. Finally, Credit Suisse Group downgraded Humanigen from a "neutral" rating to an "underperform" rating in a report on Wednesday, July 13th. Two investment analysts have rated the stock with a sell rating and four have issued a hold rating to the company. Based on data from MarketBeat.com, Humanigen presently has a consensus rating of "Hold" and a consensus target price of $18.50.

Humanigen Stock Performance

Shares of NASDAQ:HGEN opened at $0.38 on Tuesday. The business's 50 day moving average price is $1.38 and its 200-day moving average price is $2.06. Humanigen has a fifty-two week low of $0.35 and a fifty-two week high of $18.22. The company has a market cap of $27.07 million, a price-to-earnings ratio of -0.16 and a beta of -1.21.

Insider Transactions at Humanigen

In other news, insider Dale Chappell acquired 545,488 shares of the company's stock in a transaction that occurred on Friday, May 20th. The shares were bought at an average price of $2.23 per share, with a total value of $1,216,438.24. Following the completion of the purchase, the insider now directly owns 8,675,081 shares in the company, valued at $19,345,430.63. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 21.70% of the company's stock.

Receive HGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Humanigen and its competitors with MarketBeat's FREE daily newsletter.

HGEN Stock News Headlines

He's Giving Away His Ultimate Dividend Package FOR FREE!
Marc Lichtenfeld, Author of Get Rich with Dividends, is giving away his Ultimate Dividend Package, Including Details on His #1 Dividend Stock... the Safest 8% Dividend in the World... the Top Three "Extreme Dividend" Stocks... and Much, Much More. For Free. pixel
Humanigen Reports Second Quarter 2022 Financial Results
Analysts Set Humanigen, Inc. (NASDAQ:HGEN) Price Target at $9.00
He's Giving Away His Ultimate Dividend Package FOR FREE!
Marc Lichtenfeld, Author of Get Rich with Dividends, is giving away his Ultimate Dividend Package, Including Details on His #1 Dividend Stock... the Safest 8% Dividend in the World... the Top Three "Extreme Dividend" Stocks... and Much, Much More. For Free. pixel
See More Headlines
Receive HGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Humanigen and its competitors with MarketBeat's FREE daily newsletter.

HGEN Company Calendar

Last Earnings
11/12/2021
Today
8/16/2022
Next Earnings (Estimated)
11/11/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HGEN
Fax
N/A
Employees
11
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$18.50
High Stock Price Forecast
$28.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+4,913.6%
Consensus Rating
Hold
Rating Score (0-4)
1.67
Research Coverage
6 Analysts

Profitability

Net Income
$-236,650,000.00
Net Margins
-3,659.98%
Pretax Margin
-4,640.77%

Debt

Sales & Book Value

Annual Sales
$3.60 million
Book Value
($0.37) per share

Miscellaneous

Free Float
55,306,000
Market Cap
$26.06 million
Optionable
Optionable
Beta
-1.21














HGEN Stock - Frequently Asked Questions

Should I buy or sell Humanigen stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Humanigen in the last year. There are currently 2 sell ratings and 4 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" HGEN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HGEN, but not buy additional shares or sell existing shares.
View HGEN analyst ratings
or view top-rated stocks.

What is Humanigen's stock price forecast for 2022?

6 Wall Street research analysts have issued 1 year price objectives for Humanigen's stock. Their HGEN share price forecasts range from $9.00 to $28.00. On average, they expect the company's share price to reach $18.50 in the next year. This suggests a possible upside of 4,913.6% from the stock's current price.
View analysts price targets for HGEN
or view top-rated stocks among Wall Street analysts.

How have HGEN shares performed in 2022?

Humanigen's stock was trading at $3.72 at the beginning of 2022. Since then, HGEN stock has decreased by 90.1% and is now trading at $0.3690.
View the best growth stocks for 2022 here
.

When is Humanigen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, November 11th 2022.
View our HGEN earnings forecast
.

How were Humanigen's earnings last quarter?

Humanigen, Inc. (NASDAQ:HGEN) posted its earnings results on Friday, November, 12th. The company reported ($1.12) earnings per share for the quarter, missing the consensus estimate of ($0.98) by $0.14. The company had revenue of $1.04 million for the quarter, compared to analysts' expectations of $0.40 million. Humanigen had a negative trailing twelve-month return on equity of 4,882.88% and a negative net margin of 3,659.98%.

When did Humanigen's stock split?

Shares of Humanigen reverse split before market open on Monday, September 14th 2020. The 1-5 reverse split was announced on Friday, September 4th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Friday, September 11th 2020. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

What is Humanigen's stock symbol?

Humanigen trades on the NASDAQ under the ticker symbol "HGEN."

Who are Humanigen's major shareholders?

Humanigen's stock is owned by many different retail and institutional investors. Top institutional shareholders include Cowen AND Company LLC (1.60%), Silverarc Capital Management LLC (0.00%), Millennium Management LLC (0.66%), State Street Corp (0.54%), Northern Trust Corp (0.12%) and Citadel Advisors LLC (0.00%). Insiders that own company stock include Adrian Kilcoyne, Bay Ltd Nomis, Cameron Durrant, Dale Chappell and Edward P Jordan.
View institutional ownership trends
.

How do I buy shares of Humanigen?

Shares of HGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Humanigen's stock price today?

One share of HGEN stock can currently be purchased for approximately $0.37.

How much money does Humanigen make?

Humanigen (NASDAQ:HGEN) has a market capitalization of $26.06 million and generates $3.60 million in revenue each year. The company earns $-236,650,000.00 in net income (profit) each year or ($2.40) on an earnings per share basis.

How can I contact Humanigen?

Humanigen's mailing address is 533 Airport Boulevard Ste. 400, Burlingame CA, 94010. The official website for the company is www.humanigen.com. The company can be reached via phone at 650-243-3100 or via email at ir@humanigen.com.

This page (NASDAQ:HGEN) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.